Propanc Health Group Corp (OTCMKTS:PPCH) confirmed that its CEO Mr. James Nathanielsz will visit New York Coty for certain meetings with leading institutional investors. These meetings will be scheduled at the headquarters of CFSG1 Ltd.

The management view

Propanc’s CEO said that he is pleased to get this opportunity to interact with Institutional investors and let them know about the future plans of the company. They plans to schedule a roadshow, but before that they expect to complete their Scientific Advice convention with the MHRA. It is one area where the management has put in great measures to take PRP into preclinical development and preliminary patient trials.

In addition, Propanc intends to undertake several other activities including initiating first-stage partnering discussions for its lead product, working on R&D programs and an anticipated up-listing to a national stock exchange. These reported measures would help the company create value for shareholders and boost future growth.

The expectations

Propanc is working meticulously to develop unique and advanced cancer treatments for pancreatic, colorectal and ovarian cancers. They have prepared a mixture of anti-cancer compounds which put a number of effects intended to control or avert tumors from recurring and disbursing throughout the body. The products comprise or employ proenzymes, and for near-term Propanc intends to boost the development of these products into formal clinical trials for pancreatic and ovarian cancers, and later for colorectal cancer.

As per a recent market survey, the industry for these types of cancer treatment is projected to cross over $12 billion in next 5 years. Therefore, for the coming period, Propanc’s plans to advance PRP to cure early stage cancer, pre-cancerous problems and offering a preventative measure for people at risk of getting cancer.

In last trading session, the stock price of Propanc declined more than 8% to close the trading session at $0.0284.